Varian, a company of Siemens Healthineers, has received the US Food and Drug Administration (FDA) 510(k) approval for its RapidArc Dynamic solution.
RapidArc Dynamic is an advanced technology that leverages advanced algorithms to advance treatment planning to reduce the time between consultation and treatment.
Its next-generation algorithms help clinicians plan and deliver treatments rapidly and effectively and handle a high volume of cases without compromising on quality.
The dynamic collimator can be adjusted in real time, and the strategic gantry can be paused during arc rotation to provide enhanced control and ensure consistent, optimal dose delivery.
It combines the precision of modulated ports and arc therapy in a single treatment field.
The technology simplifies workflows with built-in tools such as Auto-Skin Flash, which automates and simplifies a multi-step process.
It also simplifies workflow for advanced features, including Multi-Criteria Optimization (MCO), RapidPlan, and clinical goals templates within the Eclipse treatment planning system.
Varian radiation oncology solutions president Sasa Mutic said: “RapidArc Dynamic is the latest example of Varian’s sustained investment in innovation, and ushers in a radical transformation in radiotherapy planning and delivery designed to bring flexibility to care teams using for arc therapy.
“The increased efficiency of RapidArc Dynamic to optimise plans has the potential to help decrease the time between diagnosis and treatment. Combined with significant radiation dose improvements, this is a major step in our field.”
According to the company, radiation therapy is part of the standard of care for nearly half of all cancer patients and has made significant steps to minimise dose delivery over the years.
Also, precision in radiation therapy plays an important role in improving post-treatment quality of life and reducing the risk of long-term complications as cancer patients live longer.
The RapidArc Dynamic offers advanced precision and control capabilities with the potential to significantly reduce these risks in a single solution, said the medical device company.
In the early research, RapidArc Dynamic delivered significant benefits as an optional feature of Eclipse treatment planning software on the TrueBeam 4.1 radiotherapy delivery platform.
Also, the solution reduced the dose to organs at risk by up to 50% and advanced plan optimisation and dose calculation by up to 70%.
Varian medical affairs, digital oncology vice president Sushil Beriwal said: “RapidArc Dynamic represents a powerful new solution for personalising treatment planning and delivery with the potential to further reduce doses to organs at risk which can help reduce toxicities without disrupting treatment workflow.”
